WO2019162149A1 - Process for the preparation of a nitric oxide donating prostaglandin analogue - Google Patents

Process for the preparation of a nitric oxide donating prostaglandin analogue Download PDF

Info

Publication number
WO2019162149A1
WO2019162149A1 PCT/EP2019/053455 EP2019053455W WO2019162149A1 WO 2019162149 A1 WO2019162149 A1 WO 2019162149A1 EP 2019053455 W EP2019053455 W EP 2019053455W WO 2019162149 A1 WO2019162149 A1 WO 2019162149A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
nitrooxy
process according
iii
Prior art date
Application number
PCT/EP2019/053455
Other languages
French (fr)
Inventor
Nicoletta Almirante
Original Assignee
Nicox S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox S.A. filed Critical Nicox S.A.
Priority to JP2020544224A priority Critical patent/JP7365349B2/en
Priority to US16/967,057 priority patent/US10988438B2/en
Priority to CN201980013990.3A priority patent/CN111757868B/en
Priority to CA3089530A priority patent/CA3089530A1/en
Priority to SG11202007113XA priority patent/SG11202007113XA/en
Priority to KR1020207025676A priority patent/KR20200123151A/en
Publication of WO2019162149A1 publication Critical patent/WO2019162149A1/en
Priority to PH12020551320A priority patent/PH12020551320A1/en
Priority to JP2023174240A priority patent/JP2024009896A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/02—Preparation of esters of nitric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C203/00—Esters of nitric or nitrous acid
    • C07C203/02—Esters of nitric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to an improved process for large scale preparation of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2- hepten-l-yl]-3,5-dihydroxycyclopentyl]-l-(2-phenylethyl)-2-propen-l-yl ester of formula
  • IOP-lowering agent is a prostaglandin analogue that has proved effective as IOP-lowering agent (Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E, Krauss AHP; Invest Ophthalmol Vis Sci. 2015; 56:6558-64).
  • WO 2009/136281 specifically discloses the synthesis of compound (I) and in general the preparation of l5-alkyl nitrate esters of bimatoprost.
  • WO 2009/136281 discloses the synthesis of compound of formula (I) (Example
  • the main disadvantages of the above synthesis are the use in the esterification reaction of more than an equimolar amount of 6-bromohexanoyl chloride, which presents a structural alert for potential mutagenicity, and, in the last step, the use of silver nitrate that generates a large amount of silver salts in wastewater.
  • Another main disadvantage of this process is the formation of impurities and by products such as 15 -(6-bromohexanoyl) ester of bimatoprost (compound (IX)) and l5-(6-chlorohexanoyl) ester of bimatoprost (compound (X)) which are difficult to be removed even after multiple purifications, as they have similar polarity in chromatography, similar lipophilicity and/or solubility as those of compound (I).
  • l5-(6-bromohexanoyl) ester of bimatoprost is an impurity deriving from uncompleted reaction of compound (VIII) with silver nitrate, after removal of the boronate protection.
  • l5-(6-Chlorohexanoyl) ester of bimatoprost is a by-product formed by halogen exchange reaction between the bromine atom of l5-(6-bromohexanoyl) ester of bimatoprost in a boronate protected form (compound (VIII)) and the free chlorine anion of 4-dimethylaminopyridine hydrochloride formed during the esterification step.
  • WO 2009/136281 also discloses an alternative process for the preparation of l5-acylalkynitrate bimatoprost derivatives (Examples N-l and 0-1).
  • the synthesis comprises reacting bimatoprost in a boronate protected form (compound of formula (II)) with a nitrate-alkyl carboxylic acid chloride in the presence of 4-dimethylaminopyridine (DMAP) supported on resin (PS-DMAP), followed by removal of the boronate protecting group and purification using silica gel chromatography.
  • DMAP 4-dimethylaminopyridine
  • PS-DMAP 4-dimethylaminopyridine
  • WO 2009/136281 also discloses another process (Examples Ql) for the preparation of l5-acylalkynitrate bimatoprost derivatives.
  • the compounds were obtained by esterification of bimatoprost in a boronate protected form (II) with an excess of nitrate-alkyl-(p-nitrophenyl)-carboxylate in the presence of 4-dimethylaminopyridine.
  • WO 2016/155906 discloses l5-nitrooxyderivatives of fluprostenol and it reports the synthesis of the l5-nitrooxy-hexyl ester of fluprostenol isopropyl ester.
  • the compound was prepared by reacting fluprostenol isopropyl ester in a boronate protected form with (4-nitrophenyl)-6-nitrooxyhexanoate in the presence of 4-dimethylaminopyridine excess.
  • any impurity is considered as an organic material, besides the drug substance, that may influence the efficacy and safety of the pharmaceutical products. Therefore the identification of each impurity and the quantification of the impurities, especially those bearing structural alert for mutagenicity, have become a mandatory regulatory requirements.
  • the range of industrially acceptable reagents, solvents, catalysts, etc. which can be used in the synthesis of the active ingredient is limited to those having pharmaceutical industry acceptability.
  • the compound of formula (I) is an oil and its purification in large scale quantities is difficult as it cannot be crystallized, therefore the presence of impurities is a critical issue for a large scale production. Since the main sources of impurities are the intermediates and the by-products of the synthesis, the purity of the intermediates and the control of the reactions conditions are important requirements for obtaining the final product having a pharmaceutical acceptable purity.
  • compound of formula (I) can be prepared with high purity by using the 6-(nitrooxy)hexanoyl chloride intermediate efficiently prepared by ring-opening reaction of caprolactone followed by nitration.
  • the present invention provides a large scale production process that provides compound of formula (I) having a high chemical purity and, in particular, with a content of the l5-(6-chlorohexanoyl) ester of bimatoprost impurity below the safety level.
  • Object of the present invention is a process for the preparation of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-l-yl]- 3,5-dihydroxycyclopentyl]-l-(2-phenylethyl)-2-propen-l-yl ester of formula (I):
  • DMAP 4-Dimethylaminopyridine
  • Step a) is preferably carried out in an aprotic organic solvent, preferably selected from methyltertbutyl ether, N,N-dimethylformamide or dichloromethane. Most preferably the organic solvent is methyltertbutyl ether.
  • the molar ratio of compound of formula (II) to 6-(nitrooxy)hexanoyl chloride of formula (IV) preferably ranges from 1 : 1.4 to 1 : 1.6.
  • the molar ratio of compound of formula (II) to 4-dimethylaminopyridine preferably ranges from 1 :2.0 to 1 : 2.4.
  • step a) The reaction of step a) is carried out at a temperature ranging from 0°C to room temperature.
  • step b The removal of the boronate protecting group (step b) is preferably carried out by reaction with methanol at a temperature from l7°C to 24°C.
  • 6-(Nitrooxy)hexanoyl chloride of formula (IV) is preferably obtained by a process comprising the following steps:
  • M is K, Na or Li.
  • 6-(Nitrooxy)hexanoyl chloride of formula (IV) obtained in step iii) may be directly reacted with compound of formula (II) in step a) without further purification.
  • the inorganic base used in step i) is preferably potassium hydroxide.
  • Step i) is preferably carried out in a solvent selected from methanol, ethanol or isopropanol, most preferably methanol.
  • Steps ii) and iii) are carried out in dichloromethane.
  • the chlorinating reagent used in step iii) is oxalyl chloride.
  • Compound of formula (II) is obtained by reacting bimatoprost with butylboronic acid. Preferably the reaction is carried out in methyltertbutyl ether as solvent.
  • step 1) reacting 2-capro lactone of formula (V) with potassium hydroxide in methanol to obtain 6-hydroxyhexanoic acid potassium salt (compound of formula (VI) wherein M is potassium);
  • step 2) reacting 6-hydroxyhexanoic acid potassium salt with a mixture of HNO3 and H2SO4 in dichloromethane to obtain 6-(nitrooxy)hexanoic acid (compound of formula (VII));
  • step 3) reacting 6-(nitrooxy)hexanoic acid with oxalyl chloride to obtain 6-(nitrooxy)hexanoyl chloride (compound of formula (IV)) that is used without further purification;
  • step 4) reacting bimatoprost with butyl boronic acid (1.1 -1.8 eq) in methyltertbutyl ether (MTBE) at temperature around 40°C, then removing water by azeotropic distillation to obtain bimatoprost boronate (compound of formula (II));
  • step 5 reacting bimatoprost boronate (compound of formula (II)) with 6-(nitrooxy)hexanoyl chloride (IV), (1.4-1.6 equivalent) in methyltertbutyl ether in the presence of 4-dimethylaminopyridine (2.0-2.4 equivalent) at a temperature ranging from 0°C to about room temperature, to obtain the compound of formula (III);
  • step 6) reacting compound of formula (III) with methanol at room temperature for removal of protective group to obtain the crude compound of formula (I));
  • step 7) purifying the crude compound of formula (I) to obtain compound (I) having a chemical purity above 99%.
  • the process of the invention is characterized in that the 6-(nitrooxy)hexanoyl chloride (compound (IV)) intermediate is prepared with high chemical purity and high yield by ring-opening reaction of 2-caprolactone.
  • 6-(Nitrooxy)hexanoyl chloride (IV) is prepared in high purity and high yield starting from 2-caprolactone ( Figure 1 - Scheme 1); the synthesis comprises the following steps:
  • step 1) a solution of potassium hydroxide (1 equivalent) in methanol is dropwise added to a solution of 2-caprolactone (1 equivalent) in methanol; the mixture is cooled at about 5°C to 20°C and stirred for about 5 hours at l5°C to 20°C after the addition is over; the solvent is removed (temperature is equal to or below 40°C), the crude product is slurred in methyltertbutyl ether, 6-hydroxyhexanoic acid potassium salt (VI)) is filtered, washed with methyltertbutyl ether and dried. 6-Hydroxyhexanoic acid potassium salt (VI) was obtained with a 95% yield and a purity of 98.5% (' H-NMR and HC1 assay);
  • step 2 6-hydroxyhexanoic acid potassium salt (VI) (1 eq) is portion- wise added to a mixture of HNO3 (4.6 eq) and H2SO4 (3.1 eq) in dichloromethane cooled at 0°C to 5°C under nitrogen in around 30 min while keeping the temperature below lO°C; the resulting mixture is stirred around 2-3 hours at 0°C to lO°C monitoring the end of the reaction by 1 H-NMR analysis; the mixture is cooled at a temperature from 0°C to 5°C and dropwise added with a saturated sodium chloride aqueous solution in around 20 min.
  • VI 6-hydroxyhexanoic acid potassium salt
  • reaction mixture is maintained at a temperature below l0°C; the organic layer is dried over anhydrous sodium sulfate, the solvent is removed to give 6-(nitrooxy)hexanoic acid (VII) in 86-88% yield and 97% HPLC purity;
  • step 3 N,N-dimethylformamide and oxalyl chloride are dropwise added to a solution of 6-(nitrooxy)hexanoic acid (VII) in dichloromethane, keeping the temperature of the solution from 0°C to 5°C for 1 hour, then the mixture is stirred at l5°C to 30°C for 24 hours; the solvent is evaporated off to obtain 6-(nitrooxy)hexanoyl chloride (IV) in 88-97% yield that is used without further purification.
  • VII 6-(nitrooxy)hexanoic acid
  • esterification process between bimatoprost and 6-(nitrooxy)hexanoyl chloride comprises the synthesis steps disclosed below:
  • step 4) bimatoprost is added to methyltertbutyl ether, and the resulting solution is cooled to about l5°C to l8°C; successively n-butyl boronic acid (1.11-1.18 equivalents) is added in one portion and the mixture is stirred for about 1-1.5 hour at 40°C.
  • reaction mixture is cooled down to about 20°C to 25°C, filtered and the formed water is removed by azeotropic distillation of methyltertbutyl ether at a temperature equal to or below 40°C, until water content is below or equal to 0.25%, to give crude bimatoprost boronate (II) which is directly used in the next step;
  • step 5 crude bimatoprost boronate is added to methyltertbutyl ether and the resulting solution is cooled to about 0°C to 5°C, 4-dimethylaminopyridine (about 2.1-2.3 equivalent) is added, 6-(nitrooxy)hexanoyl chloride (compound (IV)) (1.5 equivalent) dissolved in methyltertbutyl ether is dropwise added keeping the temperature of the mixture at about 0°C to 5°C.
  • step 6 compound (III) is dissolved in methanol and the resulting solution is stirred for about 18 hours at l7°C to 25 °C; the conversion of compound (III) to compound (I) is monitored by 'H NMR. In case the reaction stops, the mixture is evaporated and re-dissolved in fresh methanol until complete conversion; the reaction mixture is then concentrated under vacuum at a temperature below 40°C and the crude compound (I) is isolated by standard methods of work up;
  • step 7) the obtained crude product (I) is purified by column chromatography using a silica gel column and a mixed solvent of dichloromethane and methanol to give compound (I) with an overall yield of above 60% from bimatoprost and purity above 99%.
  • the process of the invention provides compound of formula (I)) in high yield and purity while reducing the amount of by-products, in particular the amount of (S,E)-l- ((lR,2R,3S,5R)-2-((Z)-7-(ethylamino)-7-oxohept-2-enyl)-3,5-dihydroxycyclopentyl)-5- phenylpent-l-en-3-yl 6-chlorohexanoate (compound (X)) that has a structural alert for potential mutagenicity) .
  • a solution of potassium hydroxide (131.9 g, 0.98 eq.) in methanol (1250 ml, 5 vol.) was prepared under cooling at l5°C to 20°C.
  • 25 Og of 2-caprolactone (1 eq.) and methanol (625 ml, 2.5 vol.) was introduced in a 3L three-necked round-bottomed flask. The mixture was stirred until dissolution.
  • a methanol potassium hydroxide solution was added at 5°C to 20°C within 0.5 hour. The mixture was stirred for 4.5 hours at l5°C to 20°C.
  • the reaction mixture was concentrated under vacuum (at a temperature equal to or below 40°C) to give crude 6-hydroxyhexanoic acid potassium salt (489.55 g).
  • the crude was re-slurred in methyltertbutyl ether (1250 ml, 5 vol.) for 4 hours at 20°C to 25°C, filtered on a pore 3 filter, washed with methyltertbutyl ether (2x250 ml, 2x1 vol.) and dried under vacuum at (temperature equal to or below 40°C) to give 6-hydroxyhexanoic acid potassium salt (353.04 g) with 95.7% yield. Melting point 208°C. The product was analyzed by 1 H-NMR and HC1 assay.
  • This reaction is performed on a lOOg scale in order to control the reaction temperature and reducing the time of the addition of nitrating mixture. The reaction is repeated to obtain the necessary amount of 6-(nitrooxy)hexanoic acid.
  • the reaction mixture was stirred at 0°C to 5°C for 3.5 hours and 14 hours at l5°C to 20°C. TLC monitoring showed the complete reaction.
  • the media was concentrated under vacuum (temperature is equal to or below 40°C) and co-evaporated with dichloromethane (4xlL, 4x4.35 vol.) to give 6-(nitrooxy)hexanoyl chloride (240.0 1 g) with 97.7% yield.
  • Step 4 Preparation of (Z)-7-[(lS,5R,6R,7R)-3-butyl-6-[((E,3S)-3-hydroxy-5- phenyl-pent-l-enyl]-2,4-dioxa-3-borabicyclo[3.2.l)octan-7-yl]-N-ethyl-hept-5-enamide (II)
  • Methyltertbutyl ether (2800mL, l4vol.) was charged in a flask. Bimatoprost (200 g, 1 eq.) was added and the equipment was rinsed with methyltertbutyl ether (200 mL, 1 vol.). Butyl boronic acid (58.94 g, 1.13 eq.) was added to the resulting suspension in one portion, the equipment was rinsed with methyltertbutyl ether (200 mL, 1 vol.). The mixture was heated to 40°C for 1 hour. The reaction was monitored by 1 H
  • the reaction mixture was cooled to 20°C to 25°C, clarified on a glass filter and washed with methyltertbutyl ether (200 mL, 1 vol.).
  • the filtrate was charged in the 4L three-neck round bottomed flask, the equipment was rinsed with methyltertbutyl ether (100 mL, 0.5 vol.) and the media was heated at a temperature about 40°C under vacuum for azeotropic distillation.
  • Step 5 Preparation of (lS,2E)-3- ⁇ (6R,7R)-3-butyl-7[(2Z)-7-(ethylamino)-7- oxohept-2-en- 1 -yl]-2,4-dioxa-3-borabicyclo[3.2.1 ]oct-6-yl ⁇ - 1 -(2-phenylethyl)-prop-2-en- l-yl 6-(nitrooxy) hexanoate (III)
  • the mixture was stirred at 15 to 20°C for 14.5 hours. HPLC monitoring showed 99.8% conversion.
  • the reaction mixture was cooled at 0°C to 5°C and deionized water (1351 mL, 4.89 vol.) was added within 20 minutes at a maximum temperature of l5°C.
  • Step 6 Synthesis of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2- [(2Z)-7-(ethylamino)-7-oxo-2-hepten- 1 -yl]-3,5-dihydroxycyclopentyl]- 1 -(2-phenylethyl)-
  • the mixture was stirred at l7°C to 24°C for 2.40 hours monitoring the reaction by 1 H-NMR. The mixture was stirred for 15 additional hours at l6°C to 20°C. Since 'H-NMR monitoring showed no evolution, methanol was removed under vacuum at 35°C to 40°C. Methanol (918 mL, 2.82 vol.) was added to the residue and the mixture was stirred at 20°C to 25°C for 4 hours. 'H-NMR monitoring showed 94.6% of conversion. The reaction mixture was concentrated under vacuum at a temperature below 40°C. The residue was dissolved in methyltertbutyl ether (3530 mL, 10.85 vol).
  • Step 7 Purification of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2- [(2Z)-7-(ethylamino)-7-oxo-2-hepten- 1 -yl]-3,5-dihydroxycyclopentyl]- 1 -(2-phenylethyl)- 2-propen-l-yl ester (I).
  • step 6 The mixture obtained in step 6) (crude compound (I)) was divided into 4 portions and purified using silica gel column (750 g x 4, 10.34 vol.) and dichloromethane / methanol as eluent with a gradient 100:0 to 95:5 on a Combiflash. The fractions were monitored by TLC and analyzed by HPLC (%area). Fractions with HPLC (%area) > 98% were mixed and concentrated under vacuum at equal to or below 50°C to afford 188.83 g, of Compound (I) that were further charged in the 4L three-neck round-bottomed flask and dissolved in absolute ethanol (1510 mL, 8 vol), equipment was rinsed with absolute ethanol (378 mL, 2 vol).
  • Activated charcoal (l9g, 10% /w) was added and the mixture was stirred at 20°C to 25°C for 0.5 hour.
  • the charcoal was filtered and washed with absolute ethanol (189 mL, 1 vol).
  • the filtrate was concentrated under industrial vacuum at 45°C to 50°C for 2 hours then under high vacuum at 45°C to 50°C for 5 hours.
  • Monitoring by 1 H NMR in DMSO-d6 showed no residual solvents.
  • Step A Preparation of (Z)-7-[(lS,5R,6R,7R)-3-butyl-6-[((E,3S)-3-hydroxy-5- phenyl-pent-l-enyl]-2,4-dioxa-3-borabicyclo[3.2.l)octan-7-yl]-N-ethyl-hept-5-enamide
  • Butylboronic acid (1.129 eq.) was added to a solution of bimatoprost (1 g, 1 eq.) in dichloromethane (16 vol). The mixture was heated to 40°C for 1 hour, monitoring the progression of the reaction by 1 H-NMR. Solvent was removed under reduced pressure for 2 hours. Dichloromethane (l6vol.) was added and the mixture was heated to 40°C for another hour. Solvent was removed under pressure for 40 min. Dichloromethane (l6vol.) was added and the mixture was heated to 40°C for 16 hours. Solvent was evaporated and the crude product was dried under high vacuum at 40°C for 3 hours, yielding compound (II) in quantitative yield that was used in the next step without any further purification.
  • Step B Synthesis of (S,E)-l-((lS,5R,6R,7S)-3-butyl-7-((Z)-7-(ethylamino)-7- oxohept-2-en- 1 -yl)-2,4-dioxa-3-borabicyclo[3.2.1 ]octan-6-yl)-5-phenylpent- 1 -en-3-yl 6- bromo hexanoate (VIII).
  • Step C Synthesis of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-
  • Table 2 reports the yield in Compound (I) and the main impurities formed during its preparation according to the process of the invention (Example 1) and to a method discloses in WO 2009/136281 (Example 2).
  • Compound (X)) is the l5-(6-chlorohexanoyl) ester of bimatoprost that has a structural alert for potential mutagenicity.

Abstract

The present invention relates to a process for preparing the hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]- 3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester of formula (I). In accordance with the present invention, the compound (I) can be efficiently prepared with high purity by coupling bimatoprost in a boronate protected form with 6-(nitrooxy)hexanoyl chloride and removing the boronate protecting group. The 6-(nitrooxy)hexanoyl chloride intermediate is prepared by ring-opening reaction of 2-caprolactone and subsequent nitration of the 6-hydroxyhexanoic acid potassium salt with a mixture of HNO3 and H2SO4 in dichloromethane.

Description

PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE
Field of the invention
The present invention relates to an improved process for large scale preparation of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2- hepten-l-yl]-3,5-dihydroxycyclopentyl]-l-(2-phenylethyl)-2-propen-l-yl ester of formula
(I)·
Background of the invention
Hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-[(2Z)-7-(ethylamino)- 7-oxo-2-hepten- 1 -yl]-3,5-dihydroxycyclopentyl]- 1 -(2-phenylethyl)-2-propen- 1 -yl ester of formula (I)
Figure imgf000002_0001
is a prostaglandin analogue that has proved effective as IOP-lowering agent (Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E, Krauss AHP; Invest Ophthalmol Vis Sci. 2015; 56:6558-64).
A process for preparing compound of formula (I) is disclosed in WO 2009/136281.
WO 2009/136281 specifically discloses the synthesis of compound (I) and in general the preparation of l5-alkyl nitrate esters of bimatoprost.
WO 2009/136281 discloses the synthesis of compound of formula (I) (Example
B-l) by reacting bimatoprost in a boronate protected form (compound of formula (II)) with 6-bromohexanoyl chloride to give the l5-(6-bromohexanoyl) ester of bimatoprost in a boronate protected form (compound of formula (VIII)) that is converted into the nitrate derivative by silver nitrate in acetonitrile and deprotected/purified under reverse phase chromatography yielding compound of formula (I).
Figure imgf000003_0001
The main disadvantages of the above synthesis are the use in the esterification reaction of more than an equimolar amount of 6-bromohexanoyl chloride, which presents a structural alert for potential mutagenicity, and, in the last step, the use of silver nitrate that generates a large amount of silver salts in wastewater. Another main disadvantage of this process is the formation of impurities and by products such as 15 -(6-bromohexanoyl) ester of bimatoprost (compound (IX)) and l5-(6-chlorohexanoyl) ester of bimatoprost (compound (X)) which are difficult to be removed even after multiple purifications, as they have similar polarity in chromatography, similar lipophilicity and/or solubility as those of compound (I).
Figure imgf000003_0002
According to the procedure disclosed in WO 2009/136281, l5-(6-bromohexanoyl) ester of bimatoprost (compound (IX)) is an impurity deriving from uncompleted reaction of compound (VIII) with silver nitrate, after removal of the boronate protection. l5-(6-Chlorohexanoyl) ester of bimatoprost (compound (X)) is a by-product formed by halogen exchange reaction between the bromine atom of l5-(6-bromohexanoyl) ester of bimatoprost in a boronate protected form (compound (VIII)) and the free chlorine anion of 4-dimethylaminopyridine hydrochloride formed during the esterification step. The l5-(6-chlorohexanoyl) ester of bimatoprost in a boronate protected form (Villa) (Figure 3 - Scheme 3) does not react with silver nitrate and, after removal of the protective group, yields compound (X).
WO 2009/136281 also discloses an alternative process for the preparation of l5-acylalkynitrate bimatoprost derivatives (Examples N-l and 0-1). The synthesis comprises reacting bimatoprost in a boronate protected form (compound of formula (II)) with a nitrate-alkyl carboxylic acid chloride in the presence of 4-dimethylaminopyridine (DMAP) supported on resin (PS-DMAP), followed by removal of the boronate protecting group and purification using silica gel chromatography.
The above process avoids the use of 6-bromohexanoyl chloride and the removal of the silver salts from the final product. However, this method presents another main disadvantage that is the use of 4-dimethylaminopyridine supported on resin which makes the process unsuitable for commercial scale-up and expensive. Furthermore, nitrate-alkyl carboxylic acid chloride is added in two successive steps and in high excess with respect to compound of formula (II), indeed the alkyl carboxylic acid chloride is added in an amount from about 2 to 4 equivalents.
WO 2009/136281 also discloses another process (Examples Ql) for the preparation of l5-acylalkynitrate bimatoprost derivatives. In this process the compounds were obtained by esterification of bimatoprost in a boronate protected form (II) with an excess of nitrate-alkyl-(p-nitrophenyl)-carboxylate in the presence of 4-dimethylaminopyridine.
The removal of the unreacted nitrate-alky l-(p-nitrophenyl)-carboxylate and of the by-product p-nitrophenol, formed in equimolar amounts to compound of formula (I), using chromatography methods are the main disadvantages of this process.
WO 2016/155906 discloses l5-nitrooxyderivatives of fluprostenol and it reports the synthesis of the l5-nitrooxy-hexyl ester of fluprostenol isopropyl ester. The compound was prepared by reacting fluprostenol isopropyl ester in a boronate protected form with (4-nitrophenyl)-6-nitrooxyhexanoate in the presence of 4-dimethylaminopyridine excess.
As reported above the removal of the unreacted nitrate-alkyl-(p-nitrophenyl)- carboxylate and, especially, the removal of the p-nitrophenol by-product by chromatography methods are the main disadvantages of this process.
In the past few years various regulatory authorities have been emphasizing on the purity requirements and the identification of impurities in the Active Pharmaceutical Ingredients (API). Currently, any impurity is considered as an organic material, besides the drug substance, that may influence the efficacy and safety of the pharmaceutical products. Therefore the identification of each impurity and the quantification of the impurities, especially those bearing structural alert for mutagenicity, have become a mandatory regulatory requirements. In addition, since the products are intended for pharmaceutical use, the range of industrially acceptable reagents, solvents, catalysts, etc. which can be used in the synthesis of the active ingredient is limited to those having pharmaceutical industry acceptability.
The compound of formula (I) is an oil and its purification in large scale quantities is difficult as it cannot be crystallized, therefore the presence of impurities is a critical issue for a large scale production. Since the main sources of impurities are the intermediates and the by-products of the synthesis, the purity of the intermediates and the control of the reactions conditions are important requirements for obtaining the final product having a pharmaceutical acceptable purity.
The prior art processes for the preparation of compound of formula (I) have some disadvantages; e.g. the use of bromohexanoyl chloride and the reaction conditions lead to the formation of the by-product l5-(6-chlorohexanoyl) ester of bimatoprost (compound (X)) that has a structural alert for potential mutagenicity; the use of silver nitrate for the preparation of the intermediate nitrate-alkyl carboxylic acid chloride or for the nitration of the l5-(6-bromohexanoyl) ester of bimatoprost in a boronate protected form (compound (VIII)) lead to the management of a large amount of silver nitrate wastewater, moreover metal content in the Active Pharmaceutical Ingredients must satisfy specific acceptance criterion.
Thus there is a need to provide compound of formula (I)) with high purity and in a good yield.
It has been found that compound of formula (I) can be prepared with high purity by using the 6-(nitrooxy)hexanoyl chloride intermediate efficiently prepared by ring-opening reaction of caprolactone followed by nitration.
The present invention provides a large scale production process that provides compound of formula (I) having a high chemical purity and, in particular, with a content of the l5-(6-chlorohexanoyl) ester of bimatoprost impurity below the safety level.
Description of the invention
Object of the present invention is a process for the preparation of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-l-yl]- 3,5-dihydroxycyclopentyl]-l-(2-phenylethyl)-2-propen-l-yl ester of formula (I):
Figure imgf000006_0001
said process comprising the following steps: a) reacting compound of formula (II):
Figure imgf000007_0001
with 6-(nitrooxy)hexanoyl chloride of formula (IV):
Figure imgf000007_0002
in the presence of 4-dimethylaminopyridine in free form, to obtain compound of formula (III):
Figure imgf000007_0003
b) removing the boronate protective group of compound of formula (III) to obtain compound of formula (I).
4-Dimethylaminopyridine (DMAP) in free form means DMAP not bound to a resin.
Step a) is preferably carried out in an aprotic organic solvent, preferably selected from methyltertbutyl ether, N,N-dimethylformamide or dichloromethane. Most preferably the organic solvent is methyltertbutyl ether. The molar ratio of compound of formula (II) to 6-(nitrooxy)hexanoyl chloride of formula (IV) preferably ranges from 1 : 1.4 to 1 : 1.6.
The molar ratio of compound of formula (II) to 4-dimethylaminopyridine preferably ranges from 1 :2.0 to 1 : 2.4.
The reaction of step a) is carried out at a temperature ranging from 0°C to room temperature.
The removal of the boronate protecting group (step b) is preferably carried out by reaction with methanol at a temperature from l7°C to 24°C.
6-(Nitrooxy)hexanoyl chloride of formula (IV) is preferably obtained by a process comprising the following steps:
i) reacting 2-capro lactone of formula (V):
Figure imgf000008_0001
with an inorganic base selected from KOH, NaOH and LiOH to obtain 6-hydroxyhexanoic acid salt of formula (VI):
Figure imgf000008_0002
wherein M is K, Na or Li.
ii) nitrating compound of formula (VI) with a mixture of HNO3 and H2SO4 to obtain 6-(nitrooxy)hexanoic acid of formula (VII)
Figure imgf000008_0003
iii) converting 6-(nitrooxy)hexanoic acid of formula (VII) with a chlorinating reagent to 6-(nitrooxy)hexanoyl chloride of formula (IV). 6-(Nitrooxy)hexanoyl chloride of formula (IV) obtained in step iii) may be directly reacted with compound of formula (II) in step a) without further purification.
The inorganic base used in step i) is preferably potassium hydroxide.
Step i) is preferably carried out in a solvent selected from methanol, ethanol or isopropanol, most preferably methanol.
Steps ii) and iii) are carried out in dichloromethane.
The chlorinating reagent used in step iii) is oxalyl chloride.
Compound of formula (II) is obtained by reacting bimatoprost with butylboronic acid. Preferably the reaction is carried out in methyltertbutyl ether as solvent.
A preferred process for the preparation of compound (I) is described in more details in Schemes 1 and 2 (Figures 1 and 2), said process comprising:
step 1) reacting 2-capro lactone of formula (V) with potassium hydroxide in methanol to obtain 6-hydroxyhexanoic acid potassium salt (compound of formula (VI) wherein M is potassium);
step 2) reacting 6-hydroxyhexanoic acid potassium salt with a mixture of HNO3 and H2SO4 in dichloromethane to obtain 6-(nitrooxy)hexanoic acid (compound of formula (VII));
step 3) reacting 6-(nitrooxy)hexanoic acid with oxalyl chloride to obtain 6-(nitrooxy)hexanoyl chloride (compound of formula (IV)) that is used without further purification;
step 4) reacting bimatoprost with butyl boronic acid (1.1 -1.8 eq) in methyltertbutyl ether (MTBE) at temperature around 40°C, then removing water by azeotropic distillation to obtain bimatoprost boronate (compound of formula (II));
step 5) reacting bimatoprost boronate (compound of formula (II)) with 6-(nitrooxy)hexanoyl chloride (IV), (1.4-1.6 equivalent) in methyltertbutyl ether in the presence of 4-dimethylaminopyridine (2.0-2.4 equivalent) at a temperature ranging from 0°C to about room temperature, to obtain the compound of formula (III);
step 6) reacting compound of formula (III) with methanol at room temperature for removal of protective group to obtain the crude compound of formula (I));
step 7) purifying the crude compound of formula (I) to obtain compound (I) having a chemical purity above 99%.
The process of the invention is characterized in that the 6-(nitrooxy)hexanoyl chloride (compound (IV)) intermediate is prepared with high chemical purity and high yield by ring-opening reaction of 2-caprolactone.
The experimental procedures of the steps of the process of the invention are described in detail below. All steps are run under nitrogen atmosphere.
6-(Nitrooxy)hexanoyl chloride (IV) is prepared in high purity and high yield starting from 2-caprolactone (Figure 1 - Scheme 1); the synthesis comprises the following steps:
step 1) a solution of potassium hydroxide (1 equivalent) in methanol is dropwise added to a solution of 2-caprolactone (1 equivalent) in methanol; the mixture is cooled at about 5°C to 20°C and stirred for about 5 hours at l5°C to 20°C after the addition is over; the solvent is removed (temperature is equal to or below 40°C), the crude product is slurred in methyltertbutyl ether, 6-hydroxyhexanoic acid potassium salt (VI)) is filtered, washed with methyltertbutyl ether and dried. 6-Hydroxyhexanoic acid potassium salt (VI) was obtained with a 95% yield and a purity of 98.5% (' H-NMR and HC1 assay);
step 2) 6-hydroxyhexanoic acid potassium salt (VI) (1 eq) is portion- wise added to a mixture of HNO3 (4.6 eq) and H2SO4 (3.1 eq) in dichloromethane cooled at 0°C to 5°C under nitrogen in around 30 min while keeping the temperature below lO°C; the resulting mixture is stirred around 2-3 hours at 0°C to lO°C monitoring the end of the reaction by 1 H-NMR analysis; the mixture is cooled at a temperature from 0°C to 5°C and dropwise added with a saturated sodium chloride aqueous solution in around 20 min. The reaction mixture is maintained at a temperature below l0°C; the organic layer is dried over anhydrous sodium sulfate, the solvent is removed to give 6-(nitrooxy)hexanoic acid (VII) in 86-88% yield and 97% HPLC purity;
step 3) N,N-dimethylformamide and oxalyl chloride are dropwise added to a solution of 6-(nitrooxy)hexanoic acid (VII) in dichloromethane, keeping the temperature of the solution from 0°C to 5°C for 1 hour, then the mixture is stirred at l5°C to 30°C for 24 hours; the solvent is evaporated off to obtain 6-(nitrooxy)hexanoyl chloride (IV) in 88-97% yield that is used without further purification.
The esterification process between bimatoprost and 6-(nitrooxy)hexanoyl chloride comprises the synthesis steps disclosed below:
step 4) bimatoprost is added to methyltertbutyl ether, and the resulting solution is cooled to about l5°C to l8°C; successively n-butyl boronic acid (1.11-1.18 equivalents) is added in one portion and the mixture is stirred for about 1-1.5 hour at 40°C. The end of the reaction is monitored by 1 H NMR analysis; the reaction mixture is cooled down to about 20°C to 25°C, filtered and the formed water is removed by azeotropic distillation of methyltertbutyl ether at a temperature equal to or below 40°C, until water content is below or equal to 0.25%, to give crude bimatoprost boronate (II) which is directly used in the next step;
step 5) crude bimatoprost boronate is added to methyltertbutyl ether and the resulting solution is cooled to about 0°C to 5°C, 4-dimethylaminopyridine (about 2.1-2.3 equivalent) is added, 6-(nitrooxy)hexanoyl chloride (compound (IV)) (1.5 equivalent) dissolved in methyltertbutyl ether is dropwise added keeping the temperature of the mixture at about 0°C to 5°C. After the addition, the mixture is stirred at about 0°C to 5°C up to 4 hours then overnight up to l5°C to 20°C; the end of the reaction is monitored by HPLC analysis; (lS,2E)-3-{(6R,7R)-3-butyl-7[(2Z)-7-(ethylamino)-7-oxohept-2-en-l-yl]- 2,4-dioxa-3-borabicyclo[3.2.1 ]oct-6-yl} - 1 -(2-phenylethyl)-prop-2-en- 1 -yl-6-(nitrooxy) hexanoate (compound (III)) is isolated by standard work up methods (an example of work up is described in Example 1);
steps 6) compound (III) is dissolved in methanol and the resulting solution is stirred for about 18 hours at l7°C to 25 °C; the conversion of compound (III) to compound (I) is monitored by 'H NMR. In case the reaction stops, the mixture is evaporated and re-dissolved in fresh methanol until complete conversion; the reaction mixture is then concentrated under vacuum at a temperature below 40°C and the crude compound (I) is isolated by standard methods of work up;
step 7) the obtained crude product (I) is purified by column chromatography using a silica gel column and a mixed solvent of dichloromethane and methanol to give compound (I) with an overall yield of above 60% from bimatoprost and purity above 99%.
The process of the invention provides compound of formula (I)) in high yield and purity while reducing the amount of by-products, in particular the amount of (S,E)-l- ((lR,2R,3S,5R)-2-((Z)-7-(ethylamino)-7-oxohept-2-enyl)-3,5-dihydroxycyclopentyl)-5- phenylpent-l-en-3-yl 6-chlorohexanoate (compound (X)) that has a structural alert for potential mutagenicity) .
The above advantages make the process of the invention a cost effective process easily transferable to the industrial scale.
Examples
All synthesis steps described below were conducted under nitrogen atmosphere. Example 1
Synthesis of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-[(2Z)-7- (ethylamino)-7-oxo-2-hepten-l-yl]-3,5-dihydroxycyclopentyl]-l-(2-phenylethyl)-2- propen-l-yl ester (I) (Batch 1)
Synthesis of 6-(nitrooxy)hexanoyl chloride (IV)
Step 1: Synthesis of 6-hydroxyhexanoic acid potassium salt (compound (VI))
A solution of potassium hydroxide (131.9 g, 0.98 eq.) in methanol (1250 ml, 5 vol.) was prepared under cooling at l5°C to 20°C. 25 Og of 2-caprolactone (1 eq.) and methanol (625 ml, 2.5 vol.) was introduced in a 3L three-necked round-bottomed flask. The mixture was stirred until dissolution. A methanol potassium hydroxide solution was added at 5°C to 20°C within 0.5 hour. The mixture was stirred for 4.5 hours at l5°C to 20°C. The reaction mixture was concentrated under vacuum (at a temperature equal to or below 40°C) to give crude 6-hydroxyhexanoic acid potassium salt (489.55 g). The crude was re-slurred in methyltertbutyl ether (1250 ml, 5 vol.) for 4 hours at 20°C to 25°C, filtered on a pore 3 filter, washed with methyltertbutyl ether (2x250 ml, 2x1 vol.) and dried under vacuum at (temperature equal to or below 40°C) to give 6-hydroxyhexanoic acid potassium salt (353.04 g) with 95.7% yield. Melting point 208°C. The product was analyzed by 1 H-NMR and HC1 assay.
Step 2: Synthesis of 6-(nitrooxy)hexanoic acid (VII)
This reaction is performed on a lOOg scale in order to control the reaction temperature and reducing the time of the addition of nitrating mixture. The reaction is repeated to obtain the necessary amount of 6-(nitrooxy)hexanoic acid.
Fuming HNO3 (4.6 eq.) was added to concentrated H2SO4 (3.1 eq) at a temperature from 0°C to 5°C in 14 min, then CH2CI2 (20 vol.) was added at a temperature from 0°C to 5°C in 12 min. 6-Hydroxyhexanoic acid potassium salt (101.29 g, 1 eq.) was added portion- wise in 28 min at temperature below l0°C. The mixture stirred for 2.2 hours at 0°C to l0°C and the reaction was monitored by 'H-NMR showing 99.9% conversion. The mixture was cooled to 0°C to 5°C and saturated sodium chloride aqueous solution (286.71 g in 910 mL, lOvol.) was added carefully at a temperature equal to or below l0°C within 17 min. After filtration of the insolubles, the organic layer was decanted, dried over sodium sulfate and concentrated under vacuum (at a temperature equal to or below 40°C) to give 6-(nitrooxy)hexanoic acid with 87.7% yield and 97.0% HPLC purity.
Step 3: synthesis of 6-(nitrooxy)hexanoyl chloride (IV)
6-(Nitrooxy)hexanoic acid (230 g, 1 eq.) was dissolved in dichloromethane (150 mL, 5 vol.). The resulting solution was filtered on a glass fibers, washed with dichloromethane (1x50 mL, 0.65 vol.) and analyzed by Karl Fischer (water content = 0.016%). The filtrate was cooled to 0°C to 5°C under nitrogen. Subsequently N,N-dimethylformamide (1.35 mL, 0.0059 vol.) and oxalyl chloride (108.5mL, 1 eq.) were added at 0°C to 5°C within 34 minutes. The reaction mixture was stirred at 0°C to 5°C for 3.5 hours and 14 hours at l5°C to 20°C. TLC monitoring showed the complete reaction. The media was concentrated under vacuum (temperature is equal to or below 40°C) and co-evaporated with dichloromethane (4xlL, 4x4.35 vol.) to give 6-(nitrooxy)hexanoyl chloride (240.0 1 g) with 97.7% yield.
Step 4: Preparation of (Z)-7-[(lS,5R,6R,7R)-3-butyl-6-[((E,3S)-3-hydroxy-5- phenyl-pent-l-enyl]-2,4-dioxa-3-borabicyclo[3.2.l)octan-7-yl]-N-ethyl-hept-5-enamide (II)
Methyltertbutyl ether (2800mL, l4vol.) was charged in a flask. Bimatoprost (200 g, 1 eq.) was added and the equipment was rinsed with methyltertbutyl ether (200 mL, 1 vol.). Butyl boronic acid (58.94 g, 1.13 eq.) was added to the resulting suspension in one portion, the equipment was rinsed with methyltertbutyl ether (200 mL, 1 vol.). The mixture was heated to 40°C for 1 hour. The reaction was monitored by 1 H
NMR till conversion >97%.
The reaction mixture was cooled to 20°C to 25°C, clarified on a glass filter and washed with methyltertbutyl ether (200 mL, 1 vol.). The filtrate was charged in the 4L three-neck round bottomed flask, the equipment was rinsed with methyltertbutyl ether (100 mL, 0.5 vol.) and the media was heated at a temperature about 40°C under vacuum for azeotropic distillation. Rinsing with methyltertbutyl ether and azeotropic distillation was continued till the water content of (Z)-7-[(lS,5R,6R,7R)-3-butyl-6-[((E,3S)-3- hydroxy-5 -phenyl-pent- 1 -enyl]-2,4-dioxa-3-borabicyclo[3.2.1 )octan-7-yl]-N-ethyl-hept- 5-enamide (compound (II)) was equal to or below 0.25%. Compound of formula (II) was obtained with quantitative yield (281.22 g).
Step 5: Preparation of (lS,2E)-3-{(6R,7R)-3-butyl-7[(2Z)-7-(ethylamino)-7- oxohept-2-en- 1 -yl]-2,4-dioxa-3-borabicyclo[3.2.1 ]oct-6-yl} - 1 -(2-phenylethyl)-prop-2-en- l-yl 6-(nitrooxy) hexanoate (III)
Methyltertbutyl ether (3196 mL, 11.6 vol.) was charged in a 4L three-neck round- bottomed flask under nitrogen. (Z)-7-[(lS,5R,6R,7R)-3-Butyl-6-[((E,3S)-3-hydroxy-5- phenyl-pent-l-enyl]-2,4-dioxa-3-borabicyclo[3.2.l)octan-7-yl]-N-ethyl-hept-5-enamide (compound (II)) (276.48 g crude, 1 eq.) was added, equipment was rinsed with methyltertbutyl ether (398 mL, 1.44 vol). The resulting solution was analyzed by Karl-Fischer (water content= 0.072%) and cooled to 0°C to 5°C. 4-Dimethylaminopyridine (138.5 g, 2.27 eq.) was added in one portion. A solution of 6-(nitrooxy)hexanoyl chloride (172.6 g, 1.5 eq.) in methyltertbutyl ether (508 mL, 1.84 vol.) was added dropwise at 0°C to 5°C within 1 hour. The dropping funnel was rinsed with methyltertbutyl ether (32 mL, 0.12 vol.). After stirring for 24 minutes at 0°C to 5°C, HPLC monitoring showed 97.8% conversion. The mixture was stirred at 15 to 20°C for 14.5 hours. HPLC monitoring showed 99.8% conversion. The reaction mixture was cooled at 0°C to 5°C and deionized water (1351 mL, 4.89 vol.) was added within 20 minutes at a maximum temperature of l5°C.
The mixture was stirred for 5 minutes and decanted. Aqueous layer was analyzed then discarded. An aqueous solution of 1N hydrochloric acid was prepared by mixing deionized water (493 mL, 1.78 vol.) and 11.6 N hydrochloric acid (46.6 mL, 1.08 eq.). Organic layer was washed with the hydrochloric acid solution. Aqueous layer was analyzed then discarded. Organic layer was washed first with deionized water (135 lmL, 4.88 vol) then with a saturated sodium chloride solution (3x1177 mL, 3x4.25 vol.) previously prepared by mixing deionized water (3530 mL, 12.8 vol.) and sodium chloride (1175 g, 425% w/w).
Aqueous layers (pH=4 after the last washing) were analyzed and discarded. Organic layer was dried over sodium sulfate (240 g, 86.8% w/w), washed with methyltertbutyl ether (481 mL, 1.74 vol.) and concentrated under vacuum to afford (lS,2E)-3-{(6R,7R)-3-butyl-7[(2Z)-7-(ethylamino)-7-oxohept-2-en-l-yl]-2,4-dioxa-3- borabicyclo[3.2.1 ]oct-6-yl} - 1 -(2-phenylethyl)-prop-2-en- 1 -yl 6-(nitrooxy)hexanoate
(compound (III)) with quantitative yield (327 g).
Step 6: Synthesis of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2- [(2Z)-7-(ethylamino)-7-oxo-2-hepten- 1 -yl]-3,5-dihydroxycyclopentyl]- 1 -(2-phenylethyl)-
2-propen-l-yl ester (I) (crude compound).
(lS,2E)-3-{(6R,7R)-3-butyl-7[(2Z)-7-(ethylamino)-7-oxohept-2-en-l-yl]-2,4- dioxa-3-borabicyclo[3.2.1 ]oct-6-yl} - 1 -(2-phenylethyl)-prop-2-en- 1 -yl 6-(nitrooxy) hexanoate (compound (III)) (325.4 g crude, leq.) was dissolved in methanol (2873 mL, 8.83 vol.). The resulting solution was charged in the flask and equipment was rinsed with methanol (918 mL, 2.82 vol). The mixture was stirred at l7°C to 24°C for 2.40 hours monitoring the reaction by 1 H-NMR. The mixture was stirred for 15 additional hours at l6°C to 20°C. Since 'H-NMR monitoring showed no evolution, methanol was removed under vacuum at 35°C to 40°C. Methanol (918 mL, 2.82 vol.) was added to the residue and the mixture was stirred at 20°C to 25°C for 4 hours. 'H-NMR monitoring showed 94.6% of conversion. The reaction mixture was concentrated under vacuum at a temperature below 40°C. The residue was dissolved in methyltertbutyl ether (3530 mL, 10.85 vol). The resulting solution was washed with deionized water (1770 mL, 5.44 vol). The aqueous layer (pH=7) was discarded. A solution of sodium chloride (1045 g, 321% w/w) in deionized water (3134 mL, 9.63 vol.) was prepared. Organic layer was washed with the sodium chloride solution (2x1567 mL, 2x4.82 vol.). Aqueous layers were discarded. Organic layer was dried over sodium sulfate (320 g, 98% w/w), washed with methyltertbutyl ether (640mL, 1.97vol.) and concentrated under vacuum at a temperature below 40°C to afford crude compound (I) (292.77 g.) with quantitative yield.
Step 7: Purification of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2- [(2Z)-7-(ethylamino)-7-oxo-2-hepten- 1 -yl]-3,5-dihydroxycyclopentyl]- 1 -(2-phenylethyl)- 2-propen-l-yl ester (I).
The mixture obtained in step 6) (crude compound (I)) was divided into 4 portions and purified using silica gel column (750 g x 4, 10.34 vol.) and dichloromethane / methanol as eluent with a gradient 100:0 to 95:5 on a Combiflash. The fractions were monitored by TLC and analyzed by HPLC (%area). Fractions with HPLC (%area) > 98% were mixed and concentrated under vacuum at equal to or below 50°C to afford 188.83 g, of Compound (I) that were further charged in the 4L three-neck round-bottomed flask and dissolved in absolute ethanol (1510 mL, 8 vol), equipment was rinsed with absolute ethanol (378 mL, 2 vol). Activated charcoal (l9g, 10% /w) was added and the mixture was stirred at 20°C to 25°C for 0.5 hour. The charcoal was filtered and washed with absolute ethanol (189 mL, 1 vol). The filtrate was concentrated under industrial vacuum at 45°C to 50°C for 2 hours then under high vacuum at 45°C to 50°C for 5 hours. Monitoring by 1 H NMR in DMSO-d6 showed no residual solvents.
Hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-[(2Z)-7-(ethylamino)- 7-oxo-2-hepten-l-yl]-3,5-dihydroxycyclopentyl]-l-(2-phenylethyl)-2-propen-l-yl ester (I) (174.4 g.) was obtained with 63% overall yield from compound (II). HPLC purity was 99.47%
Following the same procedure described in Example 1, other two batches (2 and 3) of compound of formula (I) were prepared, Table 1 below reports the purity of compound of formula (I) of the 3 batches and the overall yield from compound (II).
Figure imgf000017_0001
Example 2 (Comparative example)
Synthesis of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-[(2Z)-7- (ethylamino)-7-oxo-2-hepten-l-yl]-3,5-dihydroxycyclopentyl]-l-(2-phenylethyl)-2- propen-l-yl ester (I) according to the procedure disclosed in WO 2009/136281 (Figure 3 - Scheme 3)
Step A: Preparation of (Z)-7-[(lS,5R,6R,7R)-3-butyl-6-[((E,3S)-3-hydroxy-5- phenyl-pent-l-enyl]-2,4-dioxa-3-borabicyclo[3.2.l)octan-7-yl]-N-ethyl-hept-5-enamide
(P)
Butylboronic acid (1.129 eq.) was added to a solution of bimatoprost (1 g, 1 eq.) in dichloromethane (16 vol). The mixture was heated to 40°C for 1 hour, monitoring the progression of the reaction by 1 H-NMR. Solvent was removed under reduced pressure for 2 hours. Dichloromethane (l6vol.) was added and the mixture was heated to 40°C for another hour. Solvent was removed under pressure for 40 min. Dichloromethane (l6vol.) was added and the mixture was heated to 40°C for 16 hours. Solvent was evaporated and the crude product was dried under high vacuum at 40°C for 3 hours, yielding compound (II) in quantitative yield that was used in the next step without any further purification.
MS: m/z = 438 [M+H]+
Step B: Synthesis of (S,E)-l-((lS,5R,6R,7S)-3-butyl-7-((Z)-7-(ethylamino)-7- oxohept-2-en- 1 -yl)-2,4-dioxa-3-borabicyclo[3.2.1 ]octan-6-yl)-5-phenylpent- 1 -en-3-yl 6- bromo hexanoate (VIII).
4-Dimethylaminopyridine (1.1 eq.) and 6-bromohexanoyl chloride (1.15 eq.) were added to a solution of compound (II) (0.8 g, 1 eq.) in dichloromethane (15.3 vol.) cooled to 0-5°C. The mixture was stirred for 0.5 hour at 0°C to 5°C and 16 hours at 20°C to 25°C.
4-Dimethylaminopyridine (0.25 eq.) and 6-bromohexanoyl chloride (0.25 eq.) were added and the mixture was stirred for 19 additional hours. The reaction was monitored by 1 H-NMR till complete conversion. The mixture was diluted with dichloromethane (15.3 vol.) and the organic solution was washed with deionized water (6.25 vol.) and brine (6.25 vol). The organic phase was dried over Na2S04 and concentrated under vacuum, to give compound (VIII) as a light yellow oil, (calculated as quantitative yield) used in the next step without further purification.
Step C: Synthesis of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3-[(lR,2R,3S,5R)-2-
[(2Z)-7-(ethylamino)-7-oxo-2-hepten- 1 -yl]-3,5-dihydroxycyclopentyl]- 1 -(2-phenylethyl)- 2-propen-l-yl ester (I)
Silver nitrate (3.72 eq.) was added to a solution of compound (VIII) (0.8 g, 1 eq.) in acetonitrile (9.4 vol.). The mixture was stirred for 18 hours at 20°C to 25°C. The conversion was monitored by 'H-NMR in DMSO.
Silver nitrate (0.5 eq.) was added and the mixture was stirred for 20 additional hours until HPLC showed 99.7% conversion.
The mixture was filtered on a Whatman filter. The filtrate was concentrated under vacuum. The residue was dissolved in ethyl acetate (30 vol). The organic phase was washed with deionized water (5 vol.) and brine (5 vol). After drying over Na2S04, the layer was concentrated under vacuum. The residue was chromatographed on silica gel column with dichloromethane / methanol 95:5 as eluent. The fractions were monitored by TLC and only fractions presenting one spot were mixed and concentrated under vacuum at a temperature equal to or below to 40°C yielding compound (I) in 86% overall yield along with 4.27% of bimatoprost.
HPLC (%area) in reverse phase showed that purity of compound (I) was 77% and the content of l5-(6-chlorohexanoyl) ester of bimatoprost (compound (X)) is 8.34%.
Figure imgf000019_0001
Table 2 reports the yield in Compound (I) and the main impurities formed during its preparation according to the process of the invention (Example 1) and to a method discloses in WO 2009/136281 (Example 2).
Compound (X)) is the l5-(6-chlorohexanoyl) ester of bimatoprost that has a structural alert for potential mutagenicity.
The results show that the process of the invention provides compound (I) having a chemical purity above 99% with a content of compound (X) from 0.15% to 0.26%, the process disclosed in the prior art leads to compound (I) having a chemical purity of 77% and a content of compound (X) of 8.34%, namely more than 30 fold higher than the amount of compound (X) formed in the process of the invention.
The results demonstrate that the process of the invention represents an improvement over the method described in the prior art.

Claims

1. A process for the preparation of hexanoic acid, 6-(nitrooxy)-, (lS,2E)-3- [(lR,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-l-yl]-3,5-dihydroxycyclopentyl]- 1 -(2-phenylethyl)-2-propen- 1 -yl ester of formula (I) :
Figure imgf000020_0001
said process comprising the following steps:
a) reacting compound of formula (II):
Figure imgf000020_0002
with 6-(nitrooxy)hexanoyl chloride of formula (IV):
Figure imgf000020_0003
in the presence of 4-dimethylaminopyridine in free form, to obtain compound of formula (III):
Figure imgf000021_0001
b) removing the boronate protective group of compound of formula (III) to obtain compound of formula (I).
2. The process according to claim 1 wherein step a) is carried out in an aprotic organic solvent.
3. The process according to claim 2 wherein the aprotic organic solvent is selected from methyltertbutyl ether, N,N-dimethylformamide or dichloromethane.
4. The process according to claim 3 wherein the aprotic organic solvent is methyltertbutyl ether.
5. The process according to any one of claims 1 to 4 wherein in step a) the molar ratio of compound of formula (II) to 6-(nitrooxy)hexanoyl chloride of formula (IV) is 1 :1.4 to 1 :1.6 and the molar ratio of compound of formula (II) to 4-dimethylaminopyridine is 1 :2.0 to 1 : 2.4.
6. The process according to any one of claims 1 to 5 wherein step a) is carried out at a temperature ranging from 0°C to room temperature.
7. The process according to any one of the preceding claims wherein
6-(nitrooxy)hexanoyl chloride of formula (IV) is obtained by a process comprising the following steps:
i) reacting 2-capro lactone of formula (V):
Figure imgf000021_0002
with an inorganic base selected from KOH, NaOH and LiOH to obtain 6-hydroxyhexanoic acid salt of formula (VI):
Figure imgf000022_0001
wherein M is K, Na or Li.
ii) nitrating compound of formula (VI) with a mixture of HNO3 and H2SO4 to obtain 6-(nitrooxy)hexanoic acid of formula (VII)
Figure imgf000022_0002
iii) converting 6-(nitrooxy)hexanoic acid of formula (VII) with a chlorinating regent to 6-(nitrooxy)hexanoyl chloride of formula (IV).
8. The process according to claim 7 wherein 6-(nitrooxy)hexanoyl chloride of formula (IV) obtained in step iii) is directly used in step a) without further purification.
9. The process according to claim 7 or 8 wherein the inorganic base used in step i) is potassium hydroxide.
10. The process according to any one of claims 7-9 wherein step i) is carried out in a solvent selected from methanol, ethanol or isopropanol.
11. The process according to claim 10 wherein the organic solvent is methanol.
12. The process according to any one of claims 7-11 wherein step ii) is carried out in dichloromethane .
13. The process according to any one of claims 7-12 wherein step iii) is carried out by using oxalyl chloride as chlorinating reagent.
14. The process according to any one of claims 7-13 wherein step iii) is carried out in dichloromethane .
15. The process according to any one of the preceding claims wherein compound of formula (II) is obtained by reacting bimatoprost with butylboronic acid.
PCT/EP2019/053455 2018-02-21 2019-02-12 Process for the preparation of a nitric oxide donating prostaglandin analogue WO2019162149A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2020544224A JP7365349B2 (en) 2018-02-21 2019-02-12 Method for producing prostaglandin analogs that donate nitric oxide
US16/967,057 US10988438B2 (en) 2018-02-21 2019-02-12 Process for the preparation of a nitric oxide donating prostaglandin analogue
CN201980013990.3A CN111757868B (en) 2018-02-21 2019-02-12 Nitric oxide donating prostaglandin analogs
CA3089530A CA3089530A1 (en) 2018-02-21 2019-02-12 Process for the preparation of a nitric oxide donating prostaglandin analogue
SG11202007113XA SG11202007113XA (en) 2018-02-21 2019-02-12 Process for the preparation of a nitric oxide donating prostaglandin analogue
KR1020207025676A KR20200123151A (en) 2018-02-21 2019-02-12 Method for preparing nitric oxide-providing prostaglandin analogs
PH12020551320A PH12020551320A1 (en) 2018-02-21 2020-08-11 Process for the preparation of a nitric oxide donating prostaglandin analogue
JP2023174240A JP2024009896A (en) 2018-02-21 2023-10-06 Process for preparation of nitric oxide-donating prostaglandin analogue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18157888.1 2018-02-21
EP18157888.1A EP3530649B1 (en) 2018-02-21 2018-02-21 Process for the preparation of a nitric oxide donating prostaglandin analogue

Publications (1)

Publication Number Publication Date
WO2019162149A1 true WO2019162149A1 (en) 2019-08-29

Family

ID=61563114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/053455 WO2019162149A1 (en) 2018-02-21 2019-02-12 Process for the preparation of a nitric oxide donating prostaglandin analogue

Country Status (14)

Country Link
US (1) US10988438B2 (en)
EP (2) EP3530649B1 (en)
JP (2) JP7365349B2 (en)
KR (1) KR20200123151A (en)
CN (1) CN111757868B (en)
AR (1) AR114262A1 (en)
CA (1) CA3089530A1 (en)
ES (2) ES2923623T3 (en)
HU (1) HUE052204T2 (en)
PH (1) PH12020551320A1 (en)
PT (1) PT3530649T (en)
SG (1) SG11202007113XA (en)
TW (1) TWI805692B (en)
WO (1) WO2019162149A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022167070A1 (en) 2021-02-03 2022-08-11 Nicox S.A. Process for the preparation of a nitric oxide donating prostaglandin analogue
WO2023041182A1 (en) 2021-09-20 2023-03-23 Nicox Sa Nitric oxide releasing prostamide as neuroprotective agent
EP4303211A1 (en) 2022-07-07 2024-01-10 Nicox S.A. Industrial process for the preparation of hexanoic acid, 6(nitrooxy)-,(1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]3,5-dihydroxycyclopentyl]-1-(2-phenyl ethyl)-2-propen-1-yl ester and high pure product

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064405T2 (en) 2019-08-05 2024-03-28 Nicox Sa Process for the preparation of a nitric oxide donating prostaglandin analogue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009136281A1 (en) 2008-05-09 2009-11-12 Nicox S.A. Nitric oxide donating prostamides
WO2016155906A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288698A (en) * 2013-05-07 2013-09-11 北京洛斯顿精细化工有限公司 Novel method for synthetizing prostaglandin analogue
JP6279409B2 (en) * 2014-06-02 2018-02-14 株式会社ダイセル Oxidation of ketones to esters using post-treated tin-substituted zeolite beta

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009136281A1 (en) 2008-05-09 2009-11-12 Nicox S.A. Nitric oxide donating prostamides
WO2016155906A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IMPAGNATIELLO F; TORIS CB; BATUGO M; PRASANNA G; BORGHI V; BASTIA E; ONGINI E; KRAUSS AHP, INVEST OPHTHALMOL VIS SCI., vol. 56, 2015, pages 6558 - 64

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022167070A1 (en) 2021-02-03 2022-08-11 Nicox S.A. Process for the preparation of a nitric oxide donating prostaglandin analogue
WO2023041182A1 (en) 2021-09-20 2023-03-23 Nicox Sa Nitric oxide releasing prostamide as neuroprotective agent
EP4303211A1 (en) 2022-07-07 2024-01-10 Nicox S.A. Industrial process for the preparation of hexanoic acid, 6(nitrooxy)-,(1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]3,5-dihydroxycyclopentyl]-1-(2-phenyl ethyl)-2-propen-1-yl ester and high pure product
WO2024008844A1 (en) 2022-07-07 2024-01-11 Nicox S.A. Industrial process for the preparation of hexanoic acid, 6-(nitrooxy)-, (1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and high pure product

Also Published As

Publication number Publication date
TWI805692B (en) 2023-06-21
EP3757089A1 (en) 2020-12-30
US20210040032A1 (en) 2021-02-11
PH12020551320A1 (en) 2021-04-26
ES2836118T3 (en) 2021-06-24
KR20200123151A (en) 2020-10-28
EP3757089B1 (en) 2022-05-11
US10988438B2 (en) 2021-04-27
CN111757868B (en) 2023-03-14
EP3530649B1 (en) 2020-09-30
ES2923623T3 (en) 2022-09-29
PT3530649T (en) 2020-12-04
CN111757868A (en) 2020-10-09
CA3089530A1 (en) 2019-08-29
SG11202007113XA (en) 2020-09-29
EP3530649A1 (en) 2019-08-28
HUE052204T2 (en) 2021-04-28
JP2024009896A (en) 2024-01-23
TW202000643A (en) 2020-01-01
JP2021514371A (en) 2021-06-10
AR114262A1 (en) 2020-08-12
JP7365349B2 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
WO2019162149A1 (en) Process for the preparation of a nitric oxide donating prostaglandin analogue
EP3882237B1 (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
WO2021023693A1 (en) Process for the preparation of a nitric oxide donating prostaglandin analogue
TW202241390A (en) Process for the preparation of a nitric oxide donating prostaglandin analogue
KR910003709B1 (en) Process for the preparation of butyl 3'-(1h-tetrazole-5-yl)oxanylrate
JP2003055377A (en) Method for producing 2-amino-6-cyclopropylamino-9h- purine
JP4572433B2 (en) Process for producing N-acetylhomopiperazines
EP1501802B1 (en) Process for the preparation of quinoline derivatives
KR100448641B1 (en) Method for producing phenyl propionic acid derivatives from 2-phenylpropionic acid by simple processing steps with high yield
WO2015177801A1 (en) Novel process for the preparation of a lactam-containing compound
JPS6213936B2 (en)
US6548692B1 (en) Method for preparing 1,2-dibromo-2,4-dicyanobutane
JPH0586000A (en) Production of 2-amino-4-fluorobenzoic acid
CN114539244A (en) Preparation method of moxifloxacin hydrochloride
CN117362210A (en) Industrial process for preparing compounds and high purity products
US20020193591A1 (en) Process for producing 5-amino-8-alkylquinolonecarboxylic acid derivative and intermediates in the production thereof
JPH0316339B2 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19706422

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3089530

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020544224

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207025676

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 19706422

Country of ref document: EP

Kind code of ref document: A1